For patients with newly diagnosed T2DM with mild hyperglycemia (HbA1c <7.5%) and in whom metformin is not tolerated or contraindicated, lifestyle therapy plus antihyperglycemic monotherapy with a DPP-4 inhibitor may be initiated with a dose titrated based on the patient’s clinical condition and baseline eGFR. Here, DPP4 is linked to type 2 diabetes mellitus.